Chen, TWW, Giani, C, Ljevar, S, Reinhorn, D, Denu, R, Bhadri, VA, Jaeger, R, Ibrahim, T, D'Ambrosio, L, Bae, S, Han, I, Garcia, AS, Abreu, MH, Ribeiro, MFSA, Mariuk-Jarema, A, Yang, V, Sbaraglia, M, Antonescu, C, Baldi, GG, Stacchiotti, S. International multicenter retrospective study of spindle cell/ sclerosing rhabdomyosarcoma (S-RMS): A PUSH platform study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3306. PMID:. IF:65.400(Q1/1D).

Cerna, JGY, Mirallas, O, Garces, VN, Puerto, DAG, Velilla, G, Pastor, PG, Puga, TG, Salgado, MAV, Martínez, A, Gonzalez, AH, Sorolla, MA, Di Muzio, A, González, M, Martinez-Garcia, MJ, Villacampa, G, Balana, C, Galceran, JC, Dienstmann, R, Sanchez, JMS, Vieito, M. Molecular landscape of IDH1/2-mutant gliomas: A Spanish multicentric cohort. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1270. PMID:. IF:65.400(Q1/1D).

Muñiz, NH, Strauss, S, Redondo, A, Palmerini, E, Gaffaro, GJM, Chamberlain, FE, Martinez, V, Ibrahim, T, Trufero, JM, Morales, CMV, Billalabeitia, EG, Lleida, RT, Jiménez, CL, Mukherjee, U, Wan, S, Ramos, R, Garcia, AMG, Moura, DD, Martin-Broto, J. Phase II of sunitinib plus nivolumab in advanced alveolar soft-part sarcoma results from the GEIS, ISG and UCL IMMUNOSARC II study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3296. PMID:. IF:65.400(Q1/1D).

Hwang, T, Kesselheim, A, Tibau, A. Magnitude of clinical benefit of cancer medicines in curative setting and health technology assessment decisions in Europe. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2893. PMID:. IF:65.400(Q1/1D).

Cardozo, AR, Tibau, A, Liu, I, Han, J, Cliff, E, Kesselheim, A. Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2894. PMID:. IF:65.400(Q1/1D).

Lopez, JS, Besora, CP, Malaret, M, Joaquín, AB, Recio, SM, Momblan, AM, Dalmau, GM, Majem, M. Evaluation of a non-pharmacological skin care intervention for the prevention and treatment of skin toxicities induced by immunotherapy in oncology patients. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3451. PMID:. IF:65.400(Q1/1D).

Blay, JY, Lleida, RT, Martin-Broto, J, Caetano, C, De Haan, JJ, Debruyne, C, Desar, I, Duffaud, F, Gelderblom, H, Gennigens, C, Italiano, A, Colomo, LJ, Lapeire, L, Mazzeo, F, Philip, J, Striefler, JK, Svobodova, M, Tala, I, Morales, CMV, Stacchiotti, S. Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular prescreening for IDH1 mutation in chondrosarcoma. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3359. PMID:. IF:65.400(Q1/1D).

Martin-Broto, J, Ospina, GM, Garcia, AS, Trufero, JM, Martinez-Garcia, J, Fidalgo, JAP, Morales, CMV, Jurado, JC, Ledesma, P, Grifman, M, Moura, DD, Muñiz, NH. CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3354. PMID:. IF:65.400(Q1/1D).